Rapid Therapeutic Science Files with FDA to Register Facility and Products


DALLAS, Aug. 04, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces that it has formally engaged FDA Compliance Solutions, LLC to begin the initial FDA regulatory process of registering their new facilities and ultimately all products. FDA Compliance Solutions, LLC will act as RTSL’s agent through the entire registration process. FDA Compliance Solutions submitted RTSL’s initial filing required by the FDA in May 2020.

This registration process will establish the initial account and fulfill preliminary FDA compliance notification requirements by documenting current domestic manufacturing locations, and product offerings in the secure approved FDA electronic directory database for all products in commercial distribution in the United States.  Registration will incorporate presentation of associated product advertising and labeling (exterior packaging, instructions for use, websites, and promotional materials).

Donal R. Schmidt, Jr., CEO states “We look forward to having our facilities and products fully registered. This will ensure our products adhere to the highest standards of safety and efficacy as required by the FDA for any type of medical product being sold in the US or abroad. Except for our cannabinoids, all our consumables and excipients are already listed in Drug Master Files (DMF) with the FDA. This is the first step in ultimately obtaining a fully compliant product in the anticipated regulatory environment related to cannabinoids.  By seeking registration in conjunction with our new ISO 13485 manufacturing laboratory facility, we are leading the cannabinoid space in the standards that the rest of the medical world utilizes.”

This effort will lay the introductory groundwork for full implementation of cGMP (current Good Manufacturing Practices) operational control.  These regulations have the force of law (Quality System Regulation – 21 CFR 820 – 06/01/97), with the primary intent of ensuring provision of safepure, and effective products.  Rapid Therapeutics’ goal of delivering quality products, while safeguarding the health of our many consumers remains the highest priority.

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI or MDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN which may or may not be blended with or without terpenes).  The Company’s RxoidTM product line is manufactured in compliance with GMP, on FDA approved equipment. Note that while non-THC cannabinoids such as CBD and CBG are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is generally the most efficient delivery method for an API other than an IV. In addition, MDI are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. MDI are, however, expensive to formulate and difficult to manufacture to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver the same dose on its first use as well as its 100th use.

RTSL’s MDI are a safe and technically superior replacement for vape pens because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or CBG or CBN directly to the systemic blood stream. This allows RTSL to address the current U.S. vape market, which is estimated to be $5 billion in annual sales.

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders as well as chronic pain and insomnia.  RTSL’s MDI products also can be purchased by consumers online, at www.rxoid.com.

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

Visit our corporate website at www.rtslco.com.

Forward-Looking Statements
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]
Phone: 800-497-6059
Fax: 877-676-8527

Source: Rapid Therapeutic Science Laboratories, Inc.

Copyright © 2020 RTSL, Inc. All Rights Reserved.




DISCLAIMER: This report is for informational purposes only, and does not represent a solicitation to buy or sell the profiled company’s securities, which trade under the symbol rtsl, nor any other securities. Neither NasdaqStocks.com nor its employees are certified financial analysts or licensed in the securities industry in any manner. The information in this marketing piece and any accompanying information is subjective opinion and may not be complete, accurate or current and was paid for directly or indirectly by shareholders of the profiled company who may or will profit as a result of the preparation, publication and distribution of this marketing piece and accompanying information. NasdaqStocks.com is owned by McmConsulting., a Wyoming Corporation who’s owners expect to be compensated three hundred thousand shares from pbc group for Consulting for a period beginning August 3rd,2020 and ending November 3rd, 2020 to publicly disseminate information about Rapid Therapeutic Science Laboratories, Inc. its products and services for potential customers and that while the company is publicly listed and its shares can be bought and sold, the purpose of this advertisement it to present information and awareness about Rapid Therapeutic Science Laboratories, Inc. and its products and services. NasdaqStocks.com also expects to garner new subscribers as part of its efforts. This marketing piece contains forward-looking statements that involve risks and uncertainties. This marketing piece contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this Report are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this Report contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this Report may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at http://www.sec.gov; readers can review all public filings by the http://www.sec.gov.


Please enter your comment!
Please enter your name here